Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

The development of drugs able to target BTK, PI3k‐delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non‐recurrent changes in oncogenic pathways and genes expression signatures. In this...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Cell Mol Med
Egile Nagusiak: Carrà, Giovanna, Nicoli, Paolo, Lingua, Marcello Francesco, Maffeo, Beatrice, Cartellà, Antonio, Circosta, Paola, Brancaccio, Mara, Parvis, Guido, Gaidano, Valentina, Guerrasio, Angelo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://ncbi.nlm.nih.gov/pubmed/31821686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14857
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak